Drug Delivery Technologies: Players, products & prospects to 2018
Drug Delivery Technology: Assessing its potential
The time when advanced drug delivery was merely a means for profitable product life extension has gone. Drug delivery is now a major component of the pharmaceutical industry’s future and critical to bringing novel therapies to market.
Indeed, without the ability to effectively deliver targeted drugs in therapeutically significant quantities, many of the gene-based agents in research would not be viable. Despite the importance of the sector, the pharmaceutical industry has not always been quick to embrace the full range of potential technologies and opportunities on offer.
With so many companies pursuing a wide range of research strategies, it is difficult for industry and commercial executives to get a balanced and independent overview of the competitive landscape.
That is why this major new 4-volume report, Drug Delivery Technologies: Players, Products and Prospects to 2018, is essential reading for everyone in the field, from niche technology specialists through to the investment community and the pharmaceutical industry itself.
By 2018 sales of products using the novel drug delivery technology assessed in this report could exceed US$58 billion
This report provides a detailed insight into the current and future market for drug delivery technology and...
Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed;
Appraises currently available products which utilise drug delivery technology and assesses their future;
Examines new product developments from major specialist drug delivery companies, critically analysing the prospects at the product level and forecasting sales;
Allows ready comparison on different technologies within a company’s portfolio;
Provides a unique window on the sector’s product launch timetable;
Includes detailed appendices which allow at-a-glance reviews of the competitive landscape for both new and up and coming products.
Use this report to...
Assess the strengths and weaknesses of competing products/technologies in the context of specific delivery sectors and development companies;
Identify and review licencing and collaboration partners;
Understand the merits and applications of the main approaches being researched;
Quantify the commercial prospects for current and future products.
Volume I
Controlled-release Delivery
The controlled-release market was worth nearly US$21 billion globally in 2008. The sector is dominated by the launch of oral controlled-release formulations in key therapeutic areas such as the central nervous system, cardiovascular, metabolic and respiratory diseases. The growth of controlled-release delivery continues to be fuelled by line extensions helping to offset the impact of generic erosion. We estimate there are around 60 approved controlled-release products which will generate global sales of over US$21.5 billion in 2009, peaking at around US$29.5 billion in 2017 as products mature and face patent expiration leading to a decline in mature product sales to US$28.9 billion by 2018. In addition, we forecast that controlled-release products in development from 17 key companies could generate additional sales of over US$5.1 billion by 2018.
Impact on product lifecycles
Controlled-release technologies, possibly more than any other approved delivery systems, have been an important tool for pharmaceutical companies to protect their branded franchises from the ever increasing and competitive generic market. These formulations play a critical role in establishing a balanced portfolio of solid dosage products and may lead to enhanced efficacy and improved patient compliance. This leads to reductions in patient costs and extending product life-cycle management for both branded and generic pharmaceuticals.
In the past, pharmaceutical companies have tended to develop controlled-release formulations as immediate-release counterparts near patent expiration. This trend is reversing and companies are developing controlled-release formulations earlier in the product life-cycle and often launching multiple formulations (immediate release, controlled release/modified release, and delayed release) in parallel to expand the potential addressable patient population and gain a significant share of competitive market places.
This report answers key questions...
The true value of nanotechnology lies in its potential to improve the solubility and enhance the efficiency of product delivery. It has been successfully applied to the commercialisation of more than 30 drugs. Regulators have published numerous white papers on the topic and established Task Forces to monitor the progress and application of this technology although there are presently no regulations specific to nanomedicine or nano-enabled medical devices.
As the field of nanotechnology gains momentum and nano-enabled platforms emerge to address the industry’s need for therapeutic, bioavailable and less toxic products, this market is expected to grow significantly over the next decade. Proof of concept data with novel compounds is accumulating and new formulations of old chemotherapeutic drugs offer the promise to revolutionise cancer therapies.
The potential of future applications:
Tissue specific delivery – targeting the delivery of small and macro molecules across biological membranes such as the blood brain barrier for CNS drugs;
Gene and vaccine delivery – non-viral delivery of genetic materials in nanohydrogels and nanocarriers with a high degree of efficiency and expression;
Controlled-release devices – design of new nanoporous, bioerodible membranes;
Increased biocompatibility – design of artificial surfaces engineering for medical and dental implants to by-pass unwanted inflammatory response;
Improved drug bioavailability and solubility – through the engineering of drugs and reagents by nanostructuring;
Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for the safe targeted delivery of toxic therapeutic drugs.
By 2018, the market could exceed US$13 billion
By 2018 the established nanotechnology product market will be US$10.2 billion. The market will mature as the number of marketed nano-enabled products doubles and second generation nanomedicines begin to emerge. These agents will address areas of high unmet clinical need and result in the formulation of approved and novel drugs which are safer, less toxic and more efficacious than first generation products.
By 2018 these second generation nanomedicines could generate sales of nearly US$2.9 billion and establish nanotechnology as an important tool in the industry’s delivery armoury. A range of proprietary delivery platforms will utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles to target a number of therapy areas such as CNS disorders, oncology and infectious diseases.
Volume III
Nucleic Acid Delivery
The nucleic acid delivery market is maturing with over 1,450 clinical trials underway worldwide. The majority of these are in early clinical development (approximately 60%) with just over 3% in Phase III trials. Our analysis indicates that up to 35 novel nucleic acid products could reach the market within our forecasting period (2008-2018). However the harsh economic environment may force companies to place promising drugs on hold as they focus on lead projects rather than multiple programmes. To date, only a handful of nucleic acid-based products have been approved for human prescription and these products rely on delivery technologies in one shape or form. We estimate the nucleic acid market was worth just over US$80 million globally in 2008.
By 2018 we anticipate the nucleic acid technology market will have matured as many of the late-stage clinical programmes come to fruition and drug delivery companies continue to overcome issues surrounding its safety and efficiency. The development of nucleic acid delivery systems will help to improve specificity whilst the development of novel polymers and lipopolymer complexes will help to carry larger DNA payloads in order to target cells and make multigene targeting a reality. We forecast that nucleic acid products in development from 11 key companies could generate additional sales of nearly US$2.3 billion by 2018. These products utilise a range of delivery platforms including viral to non-viral delivery systems, and cover gene therapies, gene agents and DNA vaccines for a variety of targets including cancer, cardiovascular and infectious diseases.
Catalysts for change
Improvements in our understanding into the underlying genetic causes of disease as well as the uptake of new mechanisms of modulating DNA such as RNA interference which will help to fuel market growth.
The development of a new generation of DNA vaccines that will provoke strong immunogenic responses and will help to determine whether this has been a sound investment for the pharma industry.
Launch of the first siRNA-based therapeutics (although progress has been dampened following the recent termination of Opko Health’s leading eye treatment at the Phase III development stage). We anticipate companies will pursue other conditions such as infectious diseases and cancer where robust preclinical studies have already been performed and where drug delivery platforms have been adopted rather than the use of naked siRNAs.
Which companies and products will dominate?
This volume will tell you!
Volume IV
Targeted Delivery
By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8.5 billion.
Despite considerable advances in drug delivery technologies, there continues to be a high unmet clinical need for safer and better-tolerated drugs. Sub-optimal compliance and failure to persist with drug treatments are important determinants of therapeutic non-response and are of significant cost to healthcare providers. Advanced targeted drug delivery technologies will help to overcome some of these issues by improving pharmacokinetics, increasing tolerability and reducing dose-limiting off-target effects.
The need for targeted delivery platforms is increasing as patients and drug regulators seek to meet these challenges.
Current and future applications
Whilst the majority of targeted delivery systems under evaluation incorporate passive carrier systems, there will be a shift towards the use of actively targeted carriers to increase the therapeutic index of existing and new products. There are significant opportunities for future commercial developments within the pharmaceutical industry. These include:
A new generation of targeted delivery systems is under development to meet these needs which should provide greater control over the selective targeting of tissue, either with active moieties or inactive moieties which may be activated within the tissue by biological (enzymes), chemical (pH) or physical means (light, ultrasound) in order to release the active agent. The multitude of delivery platforms will lend themselves to the delivery of both small molecules and macromolecules and to a variety of target sites and delivery routes.
Unique company & technology evaluation
It is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in a wider competitive and market environment.
In this report we present a précis on each of the leading delivery specialists and potential new delivery platforms and have identified their key attributes, based on a number of criteria including:
We have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom “ranking table” in each segment of the market, dependent on their relative attributes.
Multi-point evaluation and scoring assessment
Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:
The time when advanced drug delivery was merely a means for profitable product life extension has gone. Drug delivery is now a major component of the pharmaceutical industry’s future and critical to bringing novel therapies to market.
Indeed, without the ability to effectively deliver targeted drugs in therapeutically significant quantities, many of the gene-based agents in research would not be viable. Despite the importance of the sector, the pharmaceutical industry has not always been quick to embrace the full range of potential technologies and opportunities on offer.
With so many companies pursuing a wide range of research strategies, it is difficult for industry and commercial executives to get a balanced and independent overview of the competitive landscape.
That is why this major new 4-volume report, Drug Delivery Technologies: Players, Products and Prospects to 2018, is essential reading for everyone in the field, from niche technology specialists through to the investment community and the pharmaceutical industry itself.
By 2018 sales of products using the novel drug delivery technology assessed in this report could exceed US$58 billion
This report provides a detailed insight into the current and future market for drug delivery technology and...
Provides an overview of the marketplace, outlining current thinking on the technologies being researched and employed;
Appraises currently available products which utilise drug delivery technology and assesses their future;
Examines new product developments from major specialist drug delivery companies, critically analysing the prospects at the product level and forecasting sales;
Allows ready comparison on different technologies within a company’s portfolio;
Provides a unique window on the sector’s product launch timetable;
Includes detailed appendices which allow at-a-glance reviews of the competitive landscape for both new and up and coming products.
Use this report to...
Assess the strengths and weaknesses of competing products/technologies in the context of specific delivery sectors and development companies;
Identify and review licencing and collaboration partners;
Understand the merits and applications of the main approaches being researched;
Quantify the commercial prospects for current and future products.
Volume I
Controlled-release Delivery
The controlled-release market was worth nearly US$21 billion globally in 2008. The sector is dominated by the launch of oral controlled-release formulations in key therapeutic areas such as the central nervous system, cardiovascular, metabolic and respiratory diseases. The growth of controlled-release delivery continues to be fuelled by line extensions helping to offset the impact of generic erosion. We estimate there are around 60 approved controlled-release products which will generate global sales of over US$21.5 billion in 2009, peaking at around US$29.5 billion in 2017 as products mature and face patent expiration leading to a decline in mature product sales to US$28.9 billion by 2018. In addition, we forecast that controlled-release products in development from 17 key companies could generate additional sales of over US$5.1 billion by 2018.
Impact on product lifecycles
Controlled-release technologies, possibly more than any other approved delivery systems, have been an important tool for pharmaceutical companies to protect their branded franchises from the ever increasing and competitive generic market. These formulations play a critical role in establishing a balanced portfolio of solid dosage products and may lead to enhanced efficacy and improved patient compliance. This leads to reductions in patient costs and extending product life-cycle management for both branded and generic pharmaceuticals.
In the past, pharmaceutical companies have tended to develop controlled-release formulations as immediate-release counterparts near patent expiration. This trend is reversing and companies are developing controlled-release formulations earlier in the product life-cycle and often launching multiple formulations (immediate release, controlled release/modified release, and delayed release) in parallel to expand the potential addressable patient population and gain a significant share of competitive market places.
This report answers key questions...
- Who will have launched novel products by 2018 and what technologies could they be using?
- Can market leaders such as ALZA and Elan maintain their status in controlled release in the face of growing competition?
- What obstacles must companies overcome to achieve full market potential?
- What strategies are proving most productive and for which companies?
- What will the product/company landscape look like in 2018?
- Volume II
- Nano-enabled Delivery
The true value of nanotechnology lies in its potential to improve the solubility and enhance the efficiency of product delivery. It has been successfully applied to the commercialisation of more than 30 drugs. Regulators have published numerous white papers on the topic and established Task Forces to monitor the progress and application of this technology although there are presently no regulations specific to nanomedicine or nano-enabled medical devices.
As the field of nanotechnology gains momentum and nano-enabled platforms emerge to address the industry’s need for therapeutic, bioavailable and less toxic products, this market is expected to grow significantly over the next decade. Proof of concept data with novel compounds is accumulating and new formulations of old chemotherapeutic drugs offer the promise to revolutionise cancer therapies.
The potential of future applications:
Tissue specific delivery – targeting the delivery of small and macro molecules across biological membranes such as the blood brain barrier for CNS drugs;
Gene and vaccine delivery – non-viral delivery of genetic materials in nanohydrogels and nanocarriers with a high degree of efficiency and expression;
Controlled-release devices – design of new nanoporous, bioerodible membranes;
Increased biocompatibility – design of artificial surfaces engineering for medical and dental implants to by-pass unwanted inflammatory response;
Improved drug bioavailability and solubility – through the engineering of drugs and reagents by nanostructuring;
Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for the safe targeted delivery of toxic therapeutic drugs.
By 2018, the market could exceed US$13 billion
By 2018 the established nanotechnology product market will be US$10.2 billion. The market will mature as the number of marketed nano-enabled products doubles and second generation nanomedicines begin to emerge. These agents will address areas of high unmet clinical need and result in the formulation of approved and novel drugs which are safer, less toxic and more efficacious than first generation products.
By 2018 these second generation nanomedicines could generate sales of nearly US$2.9 billion and establish nanotechnology as an important tool in the industry’s delivery armoury. A range of proprietary delivery platforms will utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles to target a number of therapy areas such as CNS disorders, oncology and infectious diseases.
Volume III
Nucleic Acid Delivery
The nucleic acid delivery market is maturing with over 1,450 clinical trials underway worldwide. The majority of these are in early clinical development (approximately 60%) with just over 3% in Phase III trials. Our analysis indicates that up to 35 novel nucleic acid products could reach the market within our forecasting period (2008-2018). However the harsh economic environment may force companies to place promising drugs on hold as they focus on lead projects rather than multiple programmes. To date, only a handful of nucleic acid-based products have been approved for human prescription and these products rely on delivery technologies in one shape or form. We estimate the nucleic acid market was worth just over US$80 million globally in 2008.
By 2018 we anticipate the nucleic acid technology market will have matured as many of the late-stage clinical programmes come to fruition and drug delivery companies continue to overcome issues surrounding its safety and efficiency. The development of nucleic acid delivery systems will help to improve specificity whilst the development of novel polymers and lipopolymer complexes will help to carry larger DNA payloads in order to target cells and make multigene targeting a reality. We forecast that nucleic acid products in development from 11 key companies could generate additional sales of nearly US$2.3 billion by 2018. These products utilise a range of delivery platforms including viral to non-viral delivery systems, and cover gene therapies, gene agents and DNA vaccines for a variety of targets including cancer, cardiovascular and infectious diseases.
Catalysts for change
Improvements in our understanding into the underlying genetic causes of disease as well as the uptake of new mechanisms of modulating DNA such as RNA interference which will help to fuel market growth.
The development of a new generation of DNA vaccines that will provoke strong immunogenic responses and will help to determine whether this has been a sound investment for the pharma industry.
Launch of the first siRNA-based therapeutics (although progress has been dampened following the recent termination of Opko Health’s leading eye treatment at the Phase III development stage). We anticipate companies will pursue other conditions such as infectious diseases and cancer where robust preclinical studies have already been performed and where drug delivery platforms have been adopted rather than the use of naked siRNAs.
Which companies and products will dominate?
This volume will tell you!
Volume IV
Targeted Delivery
By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8.5 billion.
Despite considerable advances in drug delivery technologies, there continues to be a high unmet clinical need for safer and better-tolerated drugs. Sub-optimal compliance and failure to persist with drug treatments are important determinants of therapeutic non-response and are of significant cost to healthcare providers. Advanced targeted drug delivery technologies will help to overcome some of these issues by improving pharmacokinetics, increasing tolerability and reducing dose-limiting off-target effects.
The need for targeted delivery platforms is increasing as patients and drug regulators seek to meet these challenges.
Current and future applications
Whilst the majority of targeted delivery systems under evaluation incorporate passive carrier systems, there will be a shift towards the use of actively targeted carriers to increase the therapeutic index of existing and new products. There are significant opportunities for future commercial developments within the pharmaceutical industry. These include:
- Cost-effective production of antibodies and antibody fragments for drug targeting;
- Development of new polymers and biopolymers that may be utilised in the safe and efficient targeted delivery of drugs and pro-drugs into host cells;
- Development and selective targeting of macromolecules to improve intracellular uptake and tissue specificity;
- Development of inactive pro-drugs for tissue specific release;
- Extended product life-cycles through the development of targeted formulations;
- Identification of new targeting ligands to improve the targeted delivery of small molecules and macromolecules;
- Utilisation of multiple targeting ligands to address the needs of patient sub-types;
- Combined technology platforms to develop targeted therapeutics and diagnostics in a single molecule.
A new generation of targeted delivery systems is under development to meet these needs which should provide greater control over the selective targeting of tissue, either with active moieties or inactive moieties which may be activated within the tissue by biological (enzymes), chemical (pH) or physical means (light, ultrasound) in order to release the active agent. The multitude of delivery platforms will lend themselves to the delivery of both small molecules and macromolecules and to a variety of target sites and delivery routes.
Unique company & technology evaluation
It is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in a wider competitive and market environment.
In this report we present a précis on each of the leading delivery specialists and potential new delivery platforms and have identified their key attributes, based on a number of criteria including:
- Proprietary delivery technology
- Applications of the delivery technology within the pharmaceutical industry
- Management/technical expertise of the delivery specialist
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
We have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom “ranking table” in each segment of the market, dependent on their relative attributes.
Multi-point evaluation and scoring assessment
Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:
- The technology
- Comparison of delivery platforms within each area including: activated, degradation or diffusion for controlled-release systems; nano-engineered (nanocrystals, nanoparticle, nanosuspension) or nanocarriers (carbon/ceramic, dendrimer, liposome, micelle, polymeric nanoparticles) for nano-enabled delivery; viral or non-viral platforms for nucleic acid delivery and active or passive platforms for targeted delivery systems
- The application of the technology within a number of therapy areas
- Route of delivery (oral, parenteral, transdermal, implantable), delivery of small molecules/macromolecules and vaccines, additional features such as bioerodible materials etc
- The current status of the technology in clinical development or following approval
- Number of approved and marketed products, clinical or preclinical development candidates, single or multiple products.
- Competition within the technology arena
- Alternative drug delivery systems to technologies under evaluation, advantages and disadvantages over competitors.
- The drug delivery specialist’s expertise
- Number of drug delivery systems in development, strategic alliances, financial position, marketing presence.
- The product portfolio
- Drug delivery systems under evaluation, products in development, commercialisation/development partnerships.
- Potential drug sales
- Based on key events such as market, competition, patent expiry, time of entry into the market.
Contents
REPORT OVERVIEWControlled-Release Delivery Technologies
Nano-enabled Delivery Technologies
Nucleic Acid Delivery Technologies
Targeted Delivery Technologies
Competitor Ratio Analysis Summary
DRUG DELIVERY TECHNOLOGIES: CONTROLLED-RELEASE
EXECUTIVE SUMMARY
INTRODUCTION
Overview of controlled-release delivery: past, present & future
Leading controlled-release technology platforms & characteristics
Controlled delivery profiles
Drug release profiles
Controlled-release delivery: motivators & resistors
Motivators
Controlled-Release technology motivators
Resistors
Controlled-Release technology resistors
Controlled-release delivery: impact on product lifecycles
Impact of reformulation on product life-cycle
CONTROLE D-RELEASE DELIVERY
Types of controlled-release delivery used by pharma industry
Activated controlled-release delivery
Activated controlled-release delivery – ALZA’s OROS systems
Degradation controlled-release delivery
Degradation controlled-release delivery – SkyePharma’s GEOMATRIX
Diffusion controlled-release delivery
Monolithic diffusion controlled-release delivery – LaboPharm’s Contramid
Reservoir diffusion controlled-release delivery – Impax’ CMDS
Combined controlled-release delivery – Flamel’s Micropump
Advantages and disadvantages of controlled-release platforms
Current therapeutic application of controlled-release in drug delivery
Leading brands that utilise controlled-release delivery
Leading controlled-release approved drugs
Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
Leading controlled-release drug delivery companies
Leading controlled-release drug delivery companies
Partnerships & acquisitions
Strategic developmental & commercialisation partnerships
Merger & acquisitions
Recent partnerships & acquisitions in the controlled-release field
Intellectual Property
Controlled-Release patents
THE CONTROLLED-RELEASE MARKET
Now 2009
Approved controlled-release product sales
Future 2018
Global controlled-release product sales
Novel controlled-release product sales
COMPETITOR ANALYSIS
Movers & Shakers: Cutting edge or losing their grip
Movers & shakers in controlled-release drug delivery systems
COMPANY PROFILES
AlphaRx Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
AlphaRx’ product pipeline
Sales forecasts of products utilising the delivery technology
AlphaRx’ drug delivery sales
Competitor Ratio Analysis
ALZA Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
ALZA’s product pipeline
Sales forecasts of products utilising the delivery technology
ALZA’s drug delivery sales
Competitor Ratio Analysis
Antares Pharma, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Antares’ product pipeline
Sales forecasts of products utilising the delivery technology
Antares’ drug delivery sales
Competitor Ratio Analysis
Biovail Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Biovail’s product pipeline
Sales forecasts of products utilising the delivery technology
Biovail’s drug delivery sales
Competitor Ratio Analysis
Camurus AB
Proprietary delivery technology
Camurus’ Fluid Crystal CR technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Camurus AB’s product pipeline
Sales forecasts of products utilising the delivery technology
Camurus AB’s drug delivery sales
Competitor Ratio Analysis
Cerulean Pharma Inc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Cerulean’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Cipher Pharmaceuticals, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Cipher’s product pipeline
Sales forecasts of products utilising the delivery technology
Cipher’s drug delivery sales
Competitor Ratio Analysis
Debiopharm Group
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Debiopharm’s product pipeline
Sales forecasts of products utilising the delivery technology
DebioPharm’s drug delivery sales
Competitor Ratio Analysis
DelSite Biotechnologies, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
DelSite’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Depomed, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Depomed’s product pipeline
Sales forecasts of products utilising the delivery technology
Depomed’s product sales
Competitor Ratio Analysis
Durect Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Durect’s product pipeline
Sales forecasts of products utilising the delivery technology
Durect’s product sales
Competitor Ratio Analysis
Elan Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Elan’s product pipeline
Sales forecasts of products utilising the delivery technology
Elan’s drug delivery sales
Competitor Ratio Analysis
Elite Pharmaceuticals, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Elite’s product pipeline
Sales forecasts of products utilising the delivery technology
Elite’s product sales
Competitor Ratio Analysis
Endo Pharmaceuticals, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Endo’s product pipeline
Sales forecasts of products utilising the delivery technology
Endo’s product sales
Competitor Ratio Analysis
Ethypharm SA
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Ethypharm’s product pipeline
Sales forecasts of products utilising the delivery technology
Ethypharm’s product sales
Competitor Ratio Analysis
Eurand
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Eurand’s product pipeline
Sales forecasts of products utilising the delivery technology
Eurand’s product sales
Competitor Ratio Analysis
Flamel Technologies, Inc.
Proprietary delivery technology
Flamel’s Medusa technology
Flamel’s Micropump technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Flamel’s product pipeline
Sales forecasts of products utilising the delivery technology
Flamel’s product sales
Competitor Ratio Analysis
Glycologic, Ltd
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Glycologic’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
KV Pharmaceuticals, Inc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
KV’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Labopharm, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Labopharm’s product pipeline
Sales forecasts of products utilising the delivery technology
Labopharm’s product sales
Competitor Ratio Analysis
Lavipharm SA
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Lavipharm’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Nano Interface Technology
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NITI’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
OctoPlus N.V.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
OctoPlus’ product pipeline
Sales forecasts of products utilising the delivery technology
OctoPlus’ product sales
Competitor Ratio Analysis
Penwest Pharmaceuticals
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Penwest’s product pipeline
Sales forecasts of products utilising the delivery technology
Penwest’s product sales
Competitor Ratio Analysis
SCOL R Pharma, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
SCOLR’s product pipeline
Sales forecasts of products utilising the delivery technology
SCOLR’s drug delivery sales
Competitor Ratio Analysis
Shire, Plc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Shire’s product pipeline
Sales forecasts of products utilising the delivery technology
Shire’s leading drug delivery product sales
Competitor Ratio Analysis
Skinvisible, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Skinvisible’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
SkyePharma
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
SkyePharma’s product pipeline
Sales forecasts of products utilising the delivery technology
SkyePharma’s product sales
Competitor Ratio Analysis
Spherics
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Spheric’s product pipeline
Sales forecasts of products utilising the delivery technology
Spheric’s product sales
Competitor Ratio Analysis
Watson Pharmaceuticals
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Watson’s product pipeline
Sales forecasts of products utilising the delivery technology
Watson’s drug delivery sales
Competitor Ratio Analysis
APPENDIX 1
Global controlled-release approved drugs sales 2008-2018 (US$million)
APPENDIX 2
Global controlled-release developmental drugs sales 2008-2018 (US$million)
APPENDIX 3
Competitor Ratio Analysis Criteria
Key Controlled-release delivery companies by 2015
BIBLIOGRAPHY
GLOSSARY
ACRONYMS
ENDNOTES
DRUG DELIVERY TECHNOLOGIES: NANOTECHNOLOGY
EXECUTIVE SUMMARY
INTRODUCTION
Overview of nanotechnology: past, present & future
Multifunctional nanotechnology platform
Nanotechnology: motivators & resistors
Motivators
Nanotechnology motivators
Resistors
Nanotechnology resistors
Nanomedicines, formulations and product regeneration
Failure rates at each stage of clinical drug development
NANOTECHNOLOGY IN DRUG DELIVERY
Core nanotechnology used by the pharma industry
Nano-engineered drugs
Nano-carriers
Dendrimer structure
Liposome structure
Micelle structure
Polymeric nanoparticle structure - Abraxane
Current therapeutic applications of nanotechnology in drug delivery
Leading brands that utilise nanotechnology delivery
Nanotechnology-enabled approved drugs
Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
Leading nanotechnology drug delivery companies
Leading nanotechnology-enabled drug delivery companies
Partnerships & acquisitions
Strategic development & commercialisation partnerships and joint ventures
Mergers, acquisitions, start ups & spin offs
Recent partnerships & acquisitions in the nanotechnology field
Intellectual Property
Nanotechnology patents
THE NANOTECHNOLOGY MARKET
Now 2009
Leading approved nano-enabled product sales
Leading companies developing nano-enabled product sales
Future 2018
Novel nano-enabled product sales
Global nano-enabled product sales
COMPETITOR ANALYSIS
Movers & Shakers: Cutting edge or losing their grip
Movers & shakers in nanotechnology drug delivery systems
COMPANY PROFILES
Abraxis Bioscience
Proprietary delivery technology
Abraxis Protosphere - nab technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Abraxis’ product pipeline
Sales forecasts of products utilising the delivery technology
Abraxis’ sales forecasts
Competitor Ratio Analysis
Access Pharmaceuticals
Proprietary delivery technology
ProLindac nanoparticulate prodrug
Cobalamin coated nanoparticulates
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Access Pharmaceuticals product pipeline
Sales forecasts of products utilising the delivery technology
Access’ sales forecasts
Competitor Ratio Analysis
AlphaRx Corporation
Proprietary delivery technology
Nanoparticle targeted delivery & uptake
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
AlphaRx’ product pipeline
Sales forecasts of products utilising the delivery technology
AlphaRx’ pharmaceuticals sales
Competitor Ratio Analysis
ALZA Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Sales forecasts of products utilising the delivery technology
ALZA’s drug delivery sales
Competitor Ratio Analysis
Aphios Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Aphios’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
APR Applied Pharma Research
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
APR’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
BioSante Pharmaceuticals
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
BioSante’s CaP product pipeline
Sales forecasts of products utilising the delivery technology
BioSante’s drug delivery sales
Competitor Ratio Analysis
Calando Pharmaceuticals
Proprietary delivery technology
Schematic of cyclodextrin polymeric nanoparticles
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Calando’s product pipeline
Sales forecasts of products utilising the delivery technology
Calando’s sales forecasts
Competitor Ratio Analysis
Camurus AB
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Camurus AB’s product pipeline
Sales forecasts of products utilising the delivery technology
Camurus AB’s drug delivery sales
Competitor Ratio Analysis
Cerulean Pharma Inc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Cerulean’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
CytImmune Sciences Inc
Proprietary delivery technology
CytImmune’s Colloidal Gold Nanoparticle Delivery
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
CytImmune’s’ product pipeline
Sales forecasts of products utilising the delivery technology
CytImmune’s sales forecasts
Competitor Ratio Analysis
Elan Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Elan’s NanoCrystal product portfolio
Sales forecasts of products utilising the delivery technology
Elan’s drug delivery sales
Competitor Ratio Analysis
Enzon Pharmaceuticals, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Enzon’s product pipeline
Sales forecasts of products utilising the delivery technology
Enzon’s targeted product sales
Competitor Ratio Analysis
Gilead Sciences
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Gilead Sciences’ product pipeline
Sales forecasts of products utilising the delivery technology
Gilead Sciences’ drug delivery sales
Competitor Ratio Analysis
Introgen Therapeutics
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Introgen’s product pipeline
Sales forecasts of products utilising the delivery technology
Introgen’s sales forecasts
Competitor Ratio Analysis
Mersana Therapeutics
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Mersana’s product pipeline
Sales forecasts of products utilising the delivery technology
Mersana’s sales forecasts
Competitor Ratio Analysis
Nano Interface Technology
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NITI’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Nano S Biotechnology GmbH
Proprietary delivery technology
S-Layer Technology Platform
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Nano S’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
NanoBio Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NanoBio’s product pipeline
Sales forecasts of products utilising the delivery technology
NanoBio’s drug delivery sales
Competitor Ratio Analysis
NanoBioMagnetics
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NanoBioMagnetics’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Nanobiotix
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Nanobiotix’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
NanoCarrier
Proprietary delivery technology
Micellar Nanoparticles
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NanoCarrier’s product pipeline
Sales forecasts of products utilising the delivery technology
NanoCarrier’s drug delivery sales
Competitor Ratio Analysis
Nanotechnology Victoria, Ltd
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NanoVic’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
NanoMaterials Technology
Proprietary delivery technology
High Gravity Controlled Precipitation (HCGP) of nanomaterials
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NanoMaterial’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Nanotherapeutics
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Nanotherapeutics’ product pipeline
Sales forecasts of products utilising the delivery technology
Nanotherapeutics’ drug delivery sales
Competitor Ratio Analysis
Novavax
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Novavax’s product pipeline
Sales forecasts of products utilising the delivery technology
Novavax’s drug delivery sales
Competitor Ratio Analysis
SkyePharma
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
SkyePharma’s product pipeline
Sales forecasts of products utilising the delivery technology
SkyePharma’s product sales
Competitor Ratio Analysis
Spherics
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Spheric’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Starpharma
Proprietary delivery technology
Dendrimer nanotechnology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Starpharma’s product pipeline
Sales forecasts of products utilising the delivery technology
Starpharma’s product sales
Competitor Ratio Analysis
APPENDIX 1
Global nanotechnology approved drugs sales 2008-2018
APPENDIX 2
Global nanotechnology developmental drugs sales 2008-2018
APPENDIX 3
Competitor Ratio Analysis Criteria
Key nanotechnology delivery companies by 2018
GLOSSARY
ACRONYMS
BIBLIOGRAPHY
ENDNOTES
DRUG DELIVERY TECHNOLOGIES: NUCLEIC ACID
EXECUTIVE SUMMARY
INTRODUCTION
Overview of delivery technologies for genetic material: past, present & future
Leading technology platforms for the delivery of genetic material
Nucleic acid delivery: motivators & resistors
Nucleic acid technology motivators
Motivators
Nucleic acid technology resistors
Resistors
ADVANCED NUCLEIC ACID DELIVERY TECHNOLOGIES
Types of nucleic acid-based products under development by the pharma industry
Viral vector delivery of nucleic acids
Schematic of gene therapy utilising HVJ envelope - virosome
Bacterial vector delivery of nucleic acids
Non-viral vector delivery of nucleic acids
Chemical Technologies
Stable nucleic acid-lipid particles
Targeted nanoparticles
Physical Technologies
Schematic of Zosano Pharma’s Patch Technology
Advantages and disadvantages of nucleic acid platforms
Current therapeutic applications for the viral and non-viral delivery of nucleic acids
Leading nucleic acid based products in development
Nucleic acid-based approved/filed drugs
Selection of gene therapies in clinical development
Selection of RNA therapeutics in clinical development
Selection of DNA vaccines in clinical development
Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
Leading nucleic acid drug delivery companies
Leading nucleic acid drug delivery specialists
Partnerships & acquisitions
Strategic developmental & commercialisation partnerships
Mergers, acquisitions & joint ventures
Recent partnerships & acquisitions in the nucleic acid field
Intellectual Property
Nucleic acid patents
THE VIRAL AND NON-VIRAL VECTOR DELIVERY MARKET
Now 2009
Approved nucleic acid product sales
Future 2018
Novel nucleic acid product sales
Global controlled release product sales
COMPETITOR ANALYSIS
Movers & Shakers: Cutting edge or losing their grip
Movers & shakers in nucleic acid drug delivery systems
COMPANY PROFILES
Alnylam Pharmaceuticals
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Alnylam’s product pipeline
Sales forecasts of products utilising the delivery technology
Alnylam’s sales forecasts
Competitor Ratio Analysis
AlphaVax, Inc.
Proprietary delivery technology
The alphavaccine platform system
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
AlphaVax’ product pipeline
Sales forecasts of products utilising the delivery technology
AlphaVax’ sales forecasts
Competitor Ratio Analysis
Altea Therapeutics, Inc
Proprietary delivery technology
Altea Therapeutics’ Passport Patch
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Altea Therapeutics’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
AP Pharma, Inc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
AP Pharma’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
ArmaGen Technologies
Proprietary delivery technology
ArmaGen’s BBB delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
ArmaGen Technologies’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
BioDelivery Sciences International
Proprietary delivery technology
Bioral Technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
BDSI’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Calando Pharmaceuticals
Proprietary delivery technology
Schematic of cyclodextrin polymeric nanoparticles
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Calando’s product pipeline
Sales forecasts of products utilising the delivery technology
Calando’s sales forecasts
Competitor Ratio Analysis
Cequent Pharmaceuticals
Proprietary delivery technology
Application in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Cequent’s product pipeline
Sales forecasts of products utilising the delivery technology
Cequent’s sales forecasts
Competitor Ratio Analysis
Copernicus Therapeutics
Proprietary delivery technology
Uptake and trafficking of condensed nanoparticle DNA
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Copernicus’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Diatos SA
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Diatos’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
DOR BioPharma, Inc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
DOR’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Expression Genetics, Inc
Proprietary delivery technology
TheraPlas Technology Platform
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
EGEN’s product pipeline
Sales forecasts of products utilising the delivery technology
EGEN’s sales forecasts
Competitor Ratio Analysis
Inovio Biomedical Corporation
Proprietary delivery technology
Inovio’s gene delivery platform
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Inovio’s product pipeline
Sales forecasts of products utilising the delivery technology
Inovio’s sales forecasts
Competitor Ratio Analysis
MaxCyte, Inc
Proprietary delivery technology
MaxCyte’s GT exvivo cell loading system
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
MaxCyte’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Nanotherapeutics
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Nanotherapeutics’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
NeoPharm
Proprietary delivery technology
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NeoPharm’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Novagali Pharma SA
Proprietary delivery technology
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Novagali’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Oxford Biomedica
Proprietary delivery technology
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Oxford Biomedica’s product pipeline
Sales forecasts of products utilising the delivery technology
Oxford Biomedica’s sales forecasts
Competitor Ratio Analysis
PCI Biotech
Proprietary delivery technology
PCI enhances siRNA’s gene silencing effect and improves gene delivery
Applications in the pharma industry
Potential applications for improving the delivery of a range of drug types
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
PCI’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Silence Therapeutics plc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Silence Therapeutics’ product pipeline
Sales forecasts of products utilising the delivery technology
Silence Therapeutics’ sales forecasts
Competitor Ratio Analysis
Targeted Genetics Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
TGEN’s product pipeline
Sales forecasts of products utilising the delivery technology
Targeted Genetics sales forecasts
Competitor Ratio Analysis
Tekmira Pharmaceuticals Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Tekmira’s product pipeline
Sales forecasts of products utilising the delivery technology
Tekmira’s sales forecasts
Competitor Ratio Analysis
TissueGene, Inc
Proprietary delivery technology
Manufacturing TissueGene-C cell mediated gene therapies
Applications in the pharma industry
Application of TissueGene-C cell mediated gene therapy in orthopaedics
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
TissueGene’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Vical, Inc.
Proprietary delivery technology
Schematic of p-DNA delivery and utilisation in DNA vaccines
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Vical’s product pipeline
Sales forecasts of products utilising the delivery technology
Vical’s sales forecasts
Competitor Ratio Analysis
Zosano Pharma, Inc
Proprietary delivery technology
ZP Patch Technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Zosano Pharma’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
APPENDIX 1
Global nucleic acid approved drugs sales 2008-2018
APPENDIX 2
Global nucleic acid developmental drugs sales 2008-2018
APPENDIX 3
Competitor Ratio Analysis Criteria
Key Nucleic acid delivery companies by 2018
GLOSSARY
ACRONYMS
ENDNOTES
DRUG DELIVERY TECHNOLOGIES: TARGETED
EXECUTIVE SUMMARY
INTRODUCTION
Overview of delivery technologies for targeted delivery: past, present & future
Leading technology platforms for systemic targeted drug delivery
Systemic targeted delivery: motivators & resistors
Motivators
Systemic targeted delivery technology motivators
Resistors
Systemic targeted delivery technology resistors
targeted DELIVE RY TE CHNOLOGIE S
Types of systemic targeted delivery platform in development in the pharma industry
Targeting ligands
Antibody fragment conjugate delivery
Antibody-directed enzyme pro-drug targeted delivery
Peptide-induced release for targeted delivery
Small molecule conjugate delivery
Nucleomic mediated targeted intranuclear delivery
Cobalamin mediated targeted intracellular delivery
Non-biological targeting platforms
Magnetically targeted delivery
Photosensitive targeted delivery
Current therapeutic applications for systemic targeted delivery
Leading systemic targeted products in development
Approved systemic and targeted drugs
Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
Leading targeted drug delivery companies
Leading systemic targeted delivery specialists
Partnerships & acquisitions
Strategic alliances
Strategic acquisitions
Recent market activity in targeted delivery companies
Intellectual Property
Targeted drug delivery patents
THE TARGETED DELIVERY MARKET
Now 2009
Approved targeted delivery product sales
Future 2018
Global targeted-release product sales
Novel targeted delivery product sales
COMPETITOR ANALYSIS
Movers & Shakers: Cutting edge or losing their grip
Movers & shakers in targeted drug delivery systems
Abraxis Biosciences
Proprietary delivery technology
Abraxis Protosphere - nab technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Abraxis’ product pipeline
Sales forecasts of products utilising the delivery technology
Abraxis’ targeted sales forecasts
Competitor Ratio Analysis
Access Pharmaceuticals
Proprietary delivery technology
Cobalamin targeted delivery
Schematic of targeted nanoparticle
Targeted delivery of cancer subtypes via folate polymer, Vitamin B12 polymer and biotin polymers
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Access Pharmaceuticals’ product pipeline
Sales forecasts of products utilising the delivery technology
Access Pharmaceuticals’ sales forecasts
Competitor Ratio Analysis
ALZA Corporation
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
ALZA’s targeted product pipeline
Sales forecasts of products utilising the delivery technology
ALZA’s drug delivery sales
Competitor Ratio Analysis
ArmaGen Technologies
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
ArmaGen Technologies’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Avidimer Therapeutics
Proprietary delivery technology
Targeted avidimer for methotrexate delivery
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Avidimer’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Calando Pharmaceuticals
Proprietary delivery technology
Schematic of Cyclosert technology
Schematic of RONDEL technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Calando’s product pipeline
Sales forecasts of products utilising the delivery technology
Calando’s sales forecasts
Competitor Ratio Analysis
Cell Therapeutics
Proprietary delivery technology
CTI’s polyglutamate polymer technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
CTI’s product pipeline
Sales forecasts of products utilising the delivery technology
CTI’s targeted drug delivery sales
Competitor Ratio Analysis
Cerulean Pharma Inc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Cerulean’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Copernicus Therapeutics
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Copernicus’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
CytImmune Sciences Inc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
CytImmune’s’ product pipeline
Sales forecasts of products utilising the delivery technology
CytImmune’s sales forecasts
Competitor Ratio Analysis
Diatos SA
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Diatos’ product pipeline
Sales forecasts of products utilising the delivery technology
Diatos’ targeted drug delivery sales
Competitor Ratio Analysis
Enzon Pharmaceuticals, Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Enzon’s product pipeline
Sales forecasts of products utilising the delivery technology
Enzon’s targeted product sales
Competitor Ratio Analysis
Endocyte Inc.
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Endocyte’s product pipeline
Sales forecasts of products utilising the delivery technology
Endocyte’s targeted drug delivery sales
Competitor Ratio Analysis
Eurand
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Eurand’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
ImmunoGen
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
ImmunoGen’s product pipeline
Sales forecasts of products utilising the delivery technology
ImmunoGen’s targeted delivery sales
Competitor Ratio Analysis
ImaRx Therapeutics
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
ImaRx’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
NanoBioMagnetics, Inc
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NanoBioMagnetics’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Nanobiotix
Proprietary delivery technology
Nanobiotix’ NanoXray
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Nanobiotix’ product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
NanoCarrier
Proprietary delivery technology
NanoCoat technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NanoCarrier’s product pipeline
Sales forecasts of products utilising the delivery technology
NanoCarrier’s targeted drug delivery sales
Competitor Ratio Analysis
Nano Interface Technology
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NITI’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
Nektar Therapeutics
Proprietary delivery technology
Large molecule conjugate delivery
Small molecule conjugate delivery
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Nektar’s product pipeline
Sales forecasts of products utilising the delivery technology
Nektar’s targeted sales forecasts
Competitor Ratio Analysis
NeoPharm
Proprietary delivery technology
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
NeoPharm’s product pipeline
Sales forecasts of products utilising the delivery technology
NeoPharm’s targeted product pipeline
Competitor Ratio Analysis
Novosom AG
Proprietary delivery technology
Schematic of SMARTICLES mechanism of targeted delivery
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Novosom’s product pipeline
Sales forecasts of products utilising the delivery technology
Competitor Ratio Analysis
PCI Biotech Holding ASA
Proprietary delivery technology
Potential applications for improving the delivery of a range of drug types
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
PCI’s product pipeline
Sales forecasts of products utilising the delivery technology
PCI’s targeted product sales
Competitor Ratio Analysis
Quest PharmaTech
Proprietary delivery technology
Applications in the pharma industry
Management/technical expertise
Competition within the delivery technology sector
Products in development/approved utilising the delivery technology
Quest Pharma Skip to top